Basic Information
| LncRNA/CircRNA Name | PART1 |
| Synonyms | NA |
| Region | GRCh38_5:60487713-60547657 |
| Ensemble | ENSG00000152931 |
| Refseq | NR_024617 |
| Regulatory Mechanism | Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Information of Cancer
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qCR, Western blotting, microarray etc. |
| Sample | cell line (LNCaP and PC3), prostate cancer tissues |
| Expression Pattern | up-regulated |
| Function Description | Down-regulation of lncRNA PART1 inhibited prostate cancer cell proliferation and accelerated cell apoptosis. PART1 induced downstream genes expression in TLR pathways including TLR3, TNFSF10 and CXCL13 to further influence prostate cancer cells, indicating its carcinogenesis on prostate cancer. LncRNA PART1 promoted cell proliferation ability and apoptosis via the inhibition of TLR pathways in prostate cancer. LncRNA PART1 could hence be considered as a new target in the treatment of prostate cancer. |
| Pubmed ID | 29261512 |
| Year | 2018 |
| Title | LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells. |
External Links
| Links for PART1 | GenBank HGNC Noncode |
| Links for prostate cancer | Omim Cosmic |